Telsey lowered its price target on Vital Farms (NASDAQ: VITL) to $26 from $35, while maintaining an Outperform rating, citing near-term headwinds in the egg industry.
The firm said it reduced its first-quarter 2026 and full-year 2026 estimates to reflect macroeconomic uncertainty and evolving promotional dynamics within the egg market. These pressures were partly attributed to a shift from last year’s undersupply to a more normalized or even oversupplied environment in 2026.
Telsey noted that commodity egg prices have declined sharply, down roughly 50%, while increased availability of specialty eggs at discounted promotional prices has disrupted retail ordering patterns. This environment has created additional competitive pressure for premium brands such as Vital Farms to attract consumers.
Store checks indicated more aggressive promotional activity among competing brands, along with an expansion of private-label pasture-raised egg offerings from major retailers including Costco, Trader Joe’s, and Whole Foods. These trends have influenced broader industry pricing, as reflected in USDA retail egg price data.
The firm said it expects supply and pricing trends to normalize as 2026 progresses. Despite lowering near-term projections, Telsey still anticipates double-digit sales growth beyond 2026, supported by improving industry fundamentals, expanded shelf space through additional SKUs, stronger product velocity driven by marketing and brand awareness, and targeted promotions aimed at customer acquisition.
Over the longer term, Telsey highlighted multi-year growth visibility supported by expansion in the company’s farming network—adding 175 farms to reach a total of 600 in 2025—as well as new production capacity from its Vital Crossroads facility in Seymour, Indiana, expected in 2027.
From a valuation perspective, the firm believes current concerns are already reflected in the stock, which is trading at approximately 5.0x EV/EBITDA. Telsey maintained its Outperform rating and set its revised $26 price target based on a roughly 10x multiple applied to its reduced 2026 EBITDA estimate of $105 million.
